BiVictriX is developing next-generation bispecific ADCs (bsADCs) designed to deliver superior tumour targeting, even in cancers with ultralow antigen expression. Our BI-CYGNI® platform unlocks new treatment possibilities across hard-to-treat cancers through rational, tumour-restricted antigen pairing.
Existing antibody-based approaches have shown considerable therapeutic benefit in a number of cancer indications, however the wider application of these drugs to more challenging settings is limited by the shared expression of the targeted antigens on healthy tissues. Thus leading to debilitating and sometimes fatal toxic side-effects associated with treatment. The lack of true cancer specificity seen with existing platforms has resulted in many antibody-based therapeutics being removed from the clinic and is one of the major factors limiting the development of this otherwise promising therapeutic class.
BiVictriX's Bi-Cygni therapeutics are engineered to selectively target unique cancer-specific twin antigen fingerprints, which are largely absent from healthy cells. The Bi-Cygni approach links the Company's in-house panel of cancer-restricted twin antigen fingerprints to generate the next generation of bispecific ADC therapeutics with enhanced therapeutic index, across a broad range of malignant indications.
Company Details
- Employees
- 13
- Founded
- 2017
- Address
- Biohub, Alderley Park, Macclesfield,cheshire Sk10 4tg,united Kingdom
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- bivictrix.com
- Keywords
- Bispecific ADC Therapeutics, Immunotherapy, Antibodies, Drug Discovery, Oncology, Leukaemia, Drug development, Biotherapeutics, solid tumours.
- HQ
- Macclesfield, Cheshire
Bivictrix Therapeutics Ltd Questions
Bivictrix Therapeutics Ltd's website is bivictrix.com
Bivictrix Therapeutics Ltd's LinkedIn profile is https://uk.linkedin.com/company/bivictrix-therapeutics-plc
Bivictrix Therapeutics Ltd has
13 employees.
View email and phone details for 13
employees at Bivictrix Therapeutics Ltd.
Bivictrix Therapeutics Ltd's industry is
Biotechnology Research
Bivictrix Therapeutics Ltd's top competitors are
Touchlight,
Biomodal,
Hvivo,
Binx Health,
Draig Therapeutics,
Lifearc,
Summit Therapeutics, Inc.,
Leica Biosystems,
Mi:rna Diagnostics,
Abselion.
Bivictrix Therapeutics Ltd's categories are Biotechnology Research
Bivictrix Therapeutics Ltd's founding year is 2017
